BioLineRx Ltd. reported impressive 2024 financial results highlighting strategic partnerships and enhanced focus on oncology and rare diseases.

The Investor Relations website contains information about BioLineRx's business for stockholders, potential investors, and financial analysts.

BioLineRx has secured $3.75 million through a registered direct offering and concurrent private placement aimed at advancing its oncological therapies.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudite...

The Investor Relations website contains information about BioLineRx's business for stockholders, potential investors, and financial analysts.

BioLineRx has reported its Q1 2025 financial results, showcasing significant advancements in drug development and corporate strategies in oncology and rare diseases.

BioLineRx provides an in-depth letter to shareholders detailing its future strategies and financial outlook following a significant licensing agreement.

BioLineRx shares insights into its third-quarter financial results and strategic initiatives aimed at enhancing shareholder value for 2024.

BioLineRx (NASDAQ: BLRX) reported unaudited Q1 2026 results and key oncology updates. Revenue was $0.5 million, mainly APHEXDA royalties, with APHEXDA Q1 sales of $2.7 million. Net loss was $2.6 million versus prior-year net income of $5.1 million, and cash/bank deposits totaled $17.4 million, supporting cash runway into H1 2027.The first patient was dosed in the Phase 1/2a GLIX1 glioblastoma trial, with additional centers participating, and new preclinical GBM data showed potent anti-tumor effects, including in temozolomide-resistant models. Enrollment continues in the motixafortide Phase 2b mPDAC trial.

- Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. for APHEXDA® (motixafortide) with $10 million upfront payment, up to $87 million in...